Pharma Business
Orion raises 2026 outlook on royalty growth
Photo: Orion Pharma Oy
Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.
-
October 22, 2026
Orion now expects net sales of EUR 2,070–2,140 million, up from EUR 2,000–2,100 million, and operating profit of EUR 730–790 million, up from EUR 650–750 million. The previous outlook was issued in July.
According to the company, royalty income grew faster than expected during the first nine months of 2026, and it expects this to continue for the rest of the year.
Orion will publish its interim report for January–September 2026 on October 28.
Published: October 22, 2026
